Drug Delivery in Cancer Treatment II Symptom Control, Cytokines, Che
The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, th
- PDF / 18,225,523 Bytes
- 112 Pages / 595.276 x 793.701 pts Page_size
- 83 Downloads / 197 Views
Drug Delivery in CancerTreatment II Symptom Control, Cytokines, Chemotherapy
Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong
Lennart Domell6f Department of Surgery Regional Hospital 70185 Orebro, Sweden
The European School of Oncology gratefully acknowledges sponsorship for the Task Force received from Pharmacia, originators and manufacturers of Port-A-Cath®, implantable drug delivery systems, CADD™, ambulatory infusion pumps, and Estracyt® and Sterecyt®, cytostatics.
ISBN-13:978-3-642-74711-3 e-ISBN-13:978-3-642-74709-0 001: 10.1007/978-3-642-74709-0 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this publication or parts thereof is only permitted under the provisions of the German Copyright Law of September 9,1965, in its version of June 24,1985, and a copyright fee must always be paid. Violations fall under the prosecution act of the German Copyright Law.
© Springer-Verlag Berlin Heidelberg 1989 Softcover reprint of the hardcover 1st edition 1989 The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.
2123/3145-543210
Foreword
The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces
Data Loading...
